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Introduction: DACCORD is an ongoing, longitudinal, non-interventional study within the German COPD
National Prospective Registry. This manuscript describes the baseline characteristics of the ﬁrst 5924
participants, recruited between November 2012 and November 2013.
Methods: The main inclusion criteria are a physician diagnosis of COPD, age 40 years, and initiating or
changing COPD maintenance medication. Data collected included: Demographic and disease character-
istics; prescribed medication; symptoms; COPD Assessment Test (CAT); modiﬁed Medical Research
Council dyspnoea score (mMRC); exacerbations; comorbidities; and forced expiratory volume in 1 s
(FEV1).
Results: Approximately 60% of the population are male, with mean age of 65.7 years and FEV1 61.6%
predicted. On entry to the study the majority of patients reported symptoms, most commonly exertional
dyspnoea (85.9%) and cough (65.7%). According to GOLD 2010, 48.6% of patients were classiﬁed as GOLD
II. GOLD 2011 classiﬁcation was inﬂuenced by the symptoms criterion: 43.7 and 45.3% of patients were
classiﬁed as GOLD B or D using CAT, compared with 26.4 and 34.0%, respectively, using mMRC. The
majority of patients were receiving a LAMA-containing regimen, with 39.4% overall receiving ICS. A total
of 78.3% of patients reported at least one comorbidity, most commonly cardiovascular.
Conclusion: In conclusion, DACCORD is a large, prospective, non-interventional study that provides an
informative and intriguing picture of the typical COPD patient in Germany.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is one of the few
chronic conditions with mortality forecast to increase over the next
decade (with one projection suggesting that COPD will be the
fourth leading cause of global mortality in 2030) [1], due (in Ger-
many at least) to a demographic shift resulting from increasing life
expectancy and low birth rates [2]. Given this, it is important to
understand the impact of the disease, and how best to manage it.
Randomized controlled trials (RCTs) generally recruit highly
selected populations, often excluding patients with signiﬁcant ororth).
Ltd. This is an open access article uunstable comorbidities. Although data from RCTs can be helpful in
informing treatment decisions, data that are more representative of
‘real-life’ populations are important. DACCORD, or Die ambulante
Versorgung mit langwirksamen Bronchodilatatoren: COPD-Regis-
ter in Deutschland (English translation: Outpatient CareWith Long-
Acting Bronchodilators: COPD Registry in Germany) is an ongoing
non-interventional study, and is, to our knowledge, the largest such
study in COPD to date. The main aim of DACCORD is to generate
data on the course of COPD under typical treatment conditions in
the community. The study is registered in the European Network of
Centres for Pharmacoepidemiology and Pharmacovigilance (http://
www.encepp.eu/encepp/viewResource.htm?id¼6316). This manu-
script describes the baseline characteristics of the ﬁrst cohort of
patients recruited into DACCORD.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study design
DACCORD is an ongoing, longitudinal, prospective non-
interventional study of two years duration within the newly
established German COPD National Prospective Registry. The ﬁrst
cohort (which is described here) is of approximately 6000 partici-
pants from 349 primary and secondary care practices distributed
throughout Germany (see the map in the supplementary material,
and the regional breakdown of patients in Supplementary Table 1).
Full details of the methods have been previously published [3]. A
second cohort of another 6000 patients is currently being recruited,
using similar inclusion criteria.
2.2. Participants
The main inclusion criteria are:
 a diagnosis of COPD fulﬁlling the German COPD Disease Man-
agement Programme (DMP) criteria (one of which is that COPD
is conﬁrmed by spirometry testing),
 age 40 years,
 initiating or changing COPD maintenance medication (given the
non-interventional nature of the study, the decision to initiate
or change medication was to have been made prior to inclusion
in DACCORD),
 current, ex- and never-smokers.
In order to recruit as broad a population as possible, patients
were excluded only if they were in the German Asthma Disease
Management Programme, or if they were participating in a rand-
omised clinical trial. All patients were to provide written informed
consent prior to inclusion. Each investigator was asked to recruit
ﬁve consecutive eligible patients; the aim was to recruit approxi-
mately 4000 patients whose treatment regimen included glyco-
pyrronium bromide and 2000 patients receiving other long-acting
inhaled bronchodilators for a control group.
2.3. Outcomes
Data collected on entry to the study included: Demographic and
disease characteristics; smoking status; prescribed medication
(both COPD and non-COPD); symptoms; COPD Assessment Test
(CAT); modiﬁedMedical Research Council dyspnoea score (mMRC);
exacerbations in the 6 months prior to entry (deﬁned based on
prescription of oral steroids and/or antibiotics or hospitalisation);
and comorbidities (collected in an electronic case report form using
prespeciﬁed headings, similar to those in the German COPD DMP e-
report form). In addition, baseline forced expiratory volume in 1 s
(FEV1) data were collected from spirometry conducted at the
investigative sites. The majority of patients were receiving main-
tenance COPD treatment at baseline; given the non-interventional
nature of the study there was no requirement either for their
treatment to be interrupted, or for short-acting bronchodilators to
be administered for lung function testing on entry to the study.
However, the value of requiring the COPD DMP as an inclusion
criterion is that it ensures that post-bronchodilator testing was
conducted at some point previously, since the COPD DMP requires
reversibility testing as part of the diagnosis and management of
COPD e speciﬁcally an FEV1/FVC ratio 70%, and an increase in
FEV1 of less than 15% and/or less than 200 mL, 10 min after inha-
lation of a short-acting b2-agonist (SABA) or 30min after inhalation
of a short-acting muscarinic antagonist (SAMA). Further, it was
anticipated that a subset of patients would undergo formal post-short acting bronchodilator evaluations as part of their standard
care on entry to the study.
Patients are being followed for a further 2 years. Full details of
the data that are being collected over this period have been
described previously [3], but to summarise: data are being collected
approximately every 3 months during standard clinic visits. At the
3-monthly visits, data on exacerbations and prescribed COPD
medication are being collected, whilst at the 1 and 2-year visits,
patients' CAT total score and FEV1 are also being captured, together
with the data collected at baseline such as comorbidities and
symptoms.
2.4. Statistical methods
All baseline data are presented descriptively only, and for the
overall population, either as mean and standard deviation (SD), or
number and percentage. Subgroups were deﬁned on age (<65,
65e75 and >75 years), inhaled corticosteroid use (ICS; yes/no), and
baseline CAT total score (<10 vs >30). The CAT <10 cut-point was
selected to match the GOLD 2011 severity classiﬁcation; the >30
cut-point was selected to match the range of scores (i.e., the top 10
values).
3. Results
3.1. Demographics and disease characteristics
The ﬁrst patient was recruited in November 2012, and the last in
November 2013. The baseline demographics of the overall popu-
lation are shown in Table 1. On entry, 87.1% of patients were already
receiving COPDmedication, with 12.9% newly-initiating treatment;
50.3% had received an inﬂuenza vaccination, 36.0% a pneumococcal
vaccination, 7.1% had undertaken pulmonary rehabilitation, 6.1%
were using oxygen, and 34.8% had undertaken a patient education
programme.
Approximately 46% of the patients were <65 years of age. As
might be anticipated, the duration since primary diagnosis
increased with increasing age group, with the proportion of current
smokers decreasing with increasing age. The two CAT subgroups
were of a similar size, each accounting for approximately 10% of the
overall population. The majority of the characteristics were similar
in the two CAT subgroups; patients in the CAT >30 group tended to
have worse FEV1 than those in the CAT <10 group, with more pa-
tients having a time since diagnosis >1 year. In the subgroup of
1561 patients with a post-bronchodilator spirometry assessment,
the mean FEV1 was 55.5% predicted.
3.2. Symptoms and health status
As the study population was recruited by routine clinical con-
sultations, the majority of patients reported experiencing symp-
toms of COPD on entry to DACCORD, with only 3.4% of the patients
reporting no symptoms (Table 2). The most commonly reported
symptoms were exertional dyspnoea (85.9%) and cough (65.7%),
which in the majority of cases was productive (59.4% of the cough
cases). Patients most commonly reported daytime as the most
bothersome time for symptoms (55.9% of patients), followed by
morning (33.2%) (Fig. 1). In the overall population, a similar pro-
portion of patients reported 2, 3 and >3 symptoms (26.9, 22.0 and
33.2%), with 38.6% of patients having baseline mMRC score 0 or 1,
and 61.3% a score of 2 or more.
The three age subgroups reported similar levels of symptoms,
although (perhaps as would be expected) with increasing age there
was a trend for increasing percentages of patients reporting dysp-
noea at rest and restricted exercise tolerance. As would be
Table 1
Baseline demographics and disease characteristics of the overall population recruited into the ﬁrst cohort of the DACCORD study, together with the subgroups with age <65,
65e75, and >75 years, and baseline CAT total score <10 and >30.
Overall population
N ¼ 5924
Age Baseline CAT score
<65 years
N ¼ 2711
65
e75 years
N ¼ 2161
>75 years
N ¼ 1052
CAT <10
N ¼ 563
CAT >30
N ¼ 538
Sex, n (%)
Male 3536 (59.7) 1551 (57.2) 1329 (61.5) 656 (62.4) 336 (59.7) 291 (54.1)
Female 2388 (40.3) 1160 (42.8) 832 (38.5) 396 (37.6) 227 (40.3) 247 (45.9)
Age (years), mean (SD) 65.7 (10.3) 56.5 (5.9) 70.2 (3.1) 80.2 (3.7) 66.8 (10.0) 65.7 (10.6)
Age groups, n (%)
<65 years 2711 (45.8) 2711 (100) 0 0 228 (40.5) 265 (49.3)
65e75 years 2161 (36.5) 0 2161 (100) 0 223 (39.6) 163 (30.3)
>75 years 1052 (17.8) 0 0 1052 (100) 112 (19.9) 110 (20.4)
BMI (kg/m2), mean (SD) 27.3 (5.6) 27.2 (6.0) 27.4 (5.4) 27.3 (4.6) 26.4 (5.0) 27.7 (6.2)
Duration since primary diagnosis, n (%)
1 year 1582 (26.7) 866 (31.9) 488 (22.6) 228 (21.7) 181 (32.1) 80 (14.9)
>1 year 4342 (73.3) 1845 (68.1) 1673 (77.4) 824 (78.3) 382 (67.9) 458 (85.1)
FEV1 (litres)a, mean (SD) 1.7 (0.7) 1.8 (0.8) 1.6 (0.7) 1.5 (0.7) 1.8 (0.7) 1.4 (0.7)
FEV1 (percent predicted)a, mean (SD) 61.6 (25.8) 60.5 (23.9) 60.7 (26.3) 66.0 (28.6) 66.0 (25.8) 53.9 (23.1)
Smoking status, n (%)
Ex-smoker 2409 (40.7) 879 (32.4) 1062 (49.1) 468 (44.5) 236 (41.9) 229 (42.6)
Current smoker 2271 (38.3) 1463 (54.0) 639 (29.6) 169 (16.1) 209 (37.1) 189 (35.1)
Non-smoker 1137 (19.2) 328 (12.1) 422 (19.5) 387 (36.8) 106 (18.8) 111 (20.6)
Missing 107 (1.8) 41 (1.5) 38 (1.8) 28 (2.7) 12 (2.1) 9 (1.7)
a Random spirometry, assessed without requirement for washout of COPD medication or additional inhalation of short-acting b2-agonist. BMI ¼ body-mass index;
FEV1 ¼ forced expiratory volume in 1 s; SD ¼ standard deviation.
Table 2
Baseline symptoms and health status of patients recruited in the DACCORD study.
Symptoms of COPD, n (%)
Overall population
N ¼ 5924
Age Baseline CAT score
<65 years
N ¼ 2711
65e75 years
N ¼ 2161
>75 years
N ¼ 1052
CAT <10
N ¼ 563
CAT >30
N ¼ 538
None 202 (3.4) 108 (4.0) 65 (3.0) 29 (2.8) 82 (14.6) 2 (0.4)
Exertional dyspnoea 5090 (85.9) 2303 (85.0) 1883 (87.1) 904 (85.9) 426 (75.7) 488 (90.7)
Dyspnoea at rest 1106 (18.7) 479 (17.7) 388 (18.0) 239 (22.7) 29 (5.2) 292 (54.3)
Chest tightness/chest pain 1427 (24.1) 649 (23.9) 499 (23.1) 279 (26.5) 43 (7.6) 275 (51.1)
Cough 3890 (65.7) 1821 (67.2) 1404 (65.0) 665 (63.2) 211 (37.5) 451 (83.8)
Wheezing or grunting 1434 (24.2) 696 (25.7) 484 (22.4) 254 (24.1) 46 (8.2) 251 (46.7)
Prolonged expiration 1164 (19.6) 520 (19.2) 425 (19.7) 219 (20.8) 64 (11.4) 193 (35.9)
Restricted exercise tolerance 3345 (56.5) 1476 (54.4) 1241 (57.4) 628 (59.7) 172 (30.6) 420 (78.1)
mMRC, mean (SD) 1.9 (1.1) (n ¼ 5918) 1.8 (1.0) (n ¼ 2709) 1.9 (1.0) (n ¼ 2158) 2.1 (1.1) (n ¼ 1051) 0.8 (0.9) (n ¼ 563) 3.0 (0.8) (n ¼ 538)
CAT, mean (SD) 20.0 (7.7) (n ¼ 5918) 20.4 (7.6) (n ¼ 2709) 19.5 (7.6) (n ¼ 2158) 20.1 (8.0) (n ¼ 1051) 6.7 (2.2) (n ¼ 563) 33.4 (2.3) (n ¼ 538)
mMRC ¼ modiﬁed Medical Research Council dyspnoea scale; CAT¼ COPD Assessment Test.
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those with CAT <10. However, in this latter group (which would be
described by GOLD as ‘less symptoms’), the majority of patients
reported at least one symptom, with 10.3% reporting >3.
3.3. Exacerbations
The proportion of patients experiencing exacerbations in the 6
months prior to entry are shown in Fig. 2. Approximately 60% of the
patients were recruited over the ﬁrst six months of recruitment
(from November 2012 to April 2013); these accounted for 63% of
the patients who reported an exacerbation history.
Although exacerbations were reported by a greater proportion
of patients receiving ICS than not receiving ICS, the difference be-
tween the two groups was relatively small. Most patients received a
combination of antibiotics and systemic steroids for the manage-
ment of their exacerbation, followed by antibiotics alone (Fig. 2).
3.4. COPD severity classiﬁcation
COPD severity classiﬁed according to GOLD 2010 is shown in theleft panel of Fig. 3. Approximately half of the patients met the cri-
terion of GOLD II (i.e., FEV1 between 50 and 80% predicted). To
classify patients according to GOLD 2011, the 6-month exacerba-
tions data were extrapolated to 12 months, and both CAT and
mMRCwere used for the symptoms criterion. Use of CAT resulted in
the majority of patients being classiﬁed as high symptoms (GOLD B
or D); mMRC gave a more equal distribution. FEV1 (either alone or
in combination with exacerbations history) was the main criterion
for assigning patients to the high risk categories (GOLD C or D;
Fig. 3, right panel).3.5. COPD maintenance medication
COPDmaintenancemedication, overall and by GOLD 2011 group
(using CAT as the symptom classiﬁcation) is listed in Table 3. As
would be expected from the study design, a large proportion of
patients across all four GOLD categories were receiving a regimen
that included a LAMA. In total, 39.4% of patients were receiving an
ICS-containing regimen: 31.2, 34.3, 41.7 and 45.4% of patients in
GOLD Groups A, B, C and D, respectively.
Fig. 1. Patients' experience of symptoms on entry to DACCORD (data missing from n¼ 32 [time of day] and n ¼ 28 [number of symptoms]). The symptoms reported were: Exertional
dyspnoea, dyspnoea at rest, chest tightness/chest pain, cough, wheezing or grunting, prolonged expiration, and restricted exercise tolerance.
Fig. 2. Patients (%) with exacerbations in the 6 months prior to study entry.
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Comorbidity data are available for 4992 of the patients recruited
into DACCORD. Of these patients, 78.3% reported at least one co-
morbidity. Cardiovascular disease was reported by more than halfof the overall DACCORD population, and in both of the CAT sub-
groups, with a prevalence that increased with increasing age group
(Table 4).
Fig. 3. COPD classiﬁcation of patients recruited into DACCORD, according to GOLD 2010 and 2011.
Table 3
Baseline concomitant COPD maintenance medication for patients recruited into the DACCORD study by GOLD 2011 category (percentage of patients).
Patients, % GOLD 2011 category (based on CAT)
A
N ¼ 372
B
N ¼ 2586
C
N ¼ 187
D
N ¼ 2682
LABA monotherapy 5.4 3.4 3.2 2.1
LAMA monotherapy 45.2 42.5 32.6 31.8
LAMA plus LABA 14.5 15.8 16.6 14.9
LABA plus ICS 8.0 4.6 3.7 2.8
LAMA plus ICS 0.5 1.4 0.5 1.7
LABA plus LAMA plus ICS 21.5 24.9 31.0 32.2
Regimen containing PDE4-inhibitor or theophylline 2.2 4.6 9.1 11.6
LABA ¼ long-acting b2-agonist; LAMA ¼ long-acting muscarinic antagonist; ICS ¼ inhaled corticosteroid; PDE4 ¼ phosphodiesterase-4 inhibitor; GOLD ¼ Global Initiative for
Chronic Obstructive Lung Disease; CAT¼ COPD Assessment Test.
Table 4
Self-reported comorbidities of patients recruited into DACCORD (number [percentage] of patients).
Patients, n (%) Overall population N ¼ 5924 Age Baseline CAT score
<65 years
N ¼ 2711
65
e75 years
N ¼ 2161
>75 years
N ¼ 1052
CAT <10
N ¼ 563
CAT >30
N ¼ 538
Cardiovascular disease 3075 (51.9) 1049 (38.7) 1270 (58.8) 756 (71.9) 288 (51.2) 303 (56.3)
Diabetes mellitus type 2 854 (14.4) 274 (10.1) 373 (17.3) 207 (19.7) 67 (11.9) 90 (16.7)
Psychiatric disorder 650 (11.0) 353 (13.0) 201 (9.3) 96 (9.1) 30 (5.3) 125 (23.2)
Sleep apnoea 476 (8.0) 186 (6.9) 206 (9.5) 84 (8.0) 34 (6.0) 65 (12.1)
Osteoporosis 405 (6.8) 118 (4.4) 172 (8.0) 115 (10.9) 26 (4.6) 60 (11.2)
Bronchial carcinoma 93 (1.6) 31 (1.1) 48 (2.2) 14 (1.3) 10 (1.8) 14 (2.6)
Bronchiectasis 76 (1.3) 33 (1.2) 30 (1.4) 13 (1.2) 5 (0.9) 10 (1.9)
Alpha-1 antitrypsin deﬁciency 14 (0.2) 11 (0.4) 3 (0.1) 0 1 (0.2) 1 (0.2)
CAT¼ COPD Assessment Test.
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Randomised clinical trials (even large, ‘landmark’, post-registration trials) typically recruit narrow, selected populations.
For example, three of the largest COPD trials, TORCH (Towards a
Revolution in COPDHealth), UPLIFT (Understanding Potential Long-
H. Worth et al. / Respiratory Medicine 111 (2016) 64e71 69Term Impacts on Function with Tiotropium) and POET-COPD (Pre-
vention of Exacerbations with Tiotropium in COPD) recruited
populations that were approximately 75% male, mean age 63e65
years, and predominantly GOLD II or III, and all three studies
recruited current or ex-smokers with a minimum smoking history
of 10 pack-years [4e6]. Recruiting narrower populations permits
more accurate characterisation of the efﬁcacy of interventions;
however, the populations recruited do not necessarily represent
the typical COPD patient. The DACCORD study, by using minimal
inclusion and exclusion criteria, recruited a population typical of
patients visiting their physician as a result of symptoms, as they
were either receiving maintenance therapy for the ﬁrst time, or
required treatment intensiﬁcation. In contrast to earlier interven-
tional studies, patients recruited into DACCORD have less severe
airﬂow limitation (17.6% of the population were classiﬁed as GOLD
I), with a much higher proportion of female participants. Although
DACCORD cannot be described as a true epidemiology study (given
the requirement for treatment initiation or change, and the selec-
tion of investigators), the population recruited is very similar to
that of a UK primary care database review, in which 17.5% of the
population had mild airﬂow limitation, 37% were current smokers,
and just under 50% were female [7], and DACCORD is therefore
likely to reﬂect a typical general COPD population using mainte-
nance medication. We therefore believe that the characteristics of
patients on entry to this study are generalizable to many other
Western countries.
One notable ﬁnding from this population was that approxi-
mately 20% are listed as ‘non-smokers’. COPD is described by GOLD
as being characterised by an enhanced inﬂammatory response to
‘noxious particles or gases’ [8]. Although tobacco smoke is the most
common causative factor, there is increasing awareness of the role
of other factors, including air pollution, occupational exposure, and
smoke from biomass fuels, and it will be interesting to follow the
progress of this subset of patients over the duration of the study.
However, we cannot completely exclude the possibility that these
patients developed COPD as a result of secondary exposure to to-
bacco smoke, or that they were incorrectly diagnosed (one of the
potential shortcomings of the less stringent oversight of a real-life
study compared with the highly-controlled environment of a
clinical trial).
For approximately 75% of patients, spirometry was conducted
on a non-washout basis, and without specifying the use of SABA to
generate post-bronchodilator FEV1 data. However, the non-
interventional protocol did not speciﬁcally prohibit use of SABA
prior to visits, so reﬂecting ‘real life’ practice in which treatment
decisions are made on such data. It is of note that the data from the
subgroup with formal post-SABA spirometry are very consistent to
the overall population. In any case, physicians take more account of
symptoms and exacerbations in the management of COPD, with
FEV1 reserved mainly to diagnosis.
This population had a high level of symptoms, with 61.3% of
patients reporting a baseline mMRC score of 2 or more. In contrast,
in the UK primary care database review mentioned above (which
did not require patients to use maintenance medication as an in-
clusion criterion, and in fact almost 15% were not using any
medication), 46.6% of patients had this level of dyspnoea [7]. In
particular, 85.9% of patients in DACCORD reported exertional
dyspnoea, yet only 56.5% reported restricted exercise tolerance.
This suggests that a proportion of patients had exertional dyspnoea
yet did not have restricted exercise tolerance e perhaps an indi-
cation of adaptation (they know they have exertional dyspnoea, so
don't exercise and therefore don't consider that they have reduced
exercise tolerance e the typical sedentary COPD patient). This
emphasises the importance of talking to patients about the impact
of the disease on their lives, and especially the degree of anyadaptation, when assessing the need for treatment modiﬁcation.
Indeed, other studies have shown that daily activity levels are
reduced even early in the progression of the disease [9,10], whilst
other studies have shown that the risk of developing COPD is higher
in patients with low levels of physical activity [11,12]. One espe-
cially surprising ﬁnding, however, is the high proportion of patients
in the CAT <10 group who reported experiencing symptoms. Again,
this could be a reﬂection of the inclusion criteria (asymptomatic
patients with a CAT score <10 are less likely to require treatment
intensiﬁcation), or could be due to unfamiliarity with the ques-
tionnaire. It is interesting, however, that the CAT <10 and CAT >30
groups have similar demographics (although there is a longer
duration of COPD in the CAT >30 group). The CAT questionnaire is
not a pure disease severity tool, but is an assessment of health
status. Since three out of the eight questions are related to chronic
bronchitis (cough, phlegm and dyspnoea), it is possible that the
>30 group included a higher proportion of patients with the
chronic bronchitis phenotype.
As would be anticipated from the study design, at baseline
muscarinic antagonist therapy (either alone or as a component of
‘triple’ therapy regimen) was the most commonly prescribed
maintenance treatment. However, a high proportion of GOLDA or B
patients were receiving ICS as part of their treatment regimen. This
is consistent with data on primary care prescribing patterns in the
UK, in which more than 50% of the COPD population (without a
concomitant asthma diagnosis) were receiving ICS [13]. Although
this cannot be described as inappropriate prescribing (since we do
not know the clinical characteristics of the patients at the time the
ICS was initiated), it does suggest that a proportion of these pa-
tients are receiving regimens other than recommended by guide-
lines or drug labels. In particular, baseline exacerbations did not
appear to correlate with use of ICS. This could either be because
patients were being treated unnecessarily with ICS, or that ICS was
preventing exacerbations. However, these ﬁndings should be
interpreted with care, as they are based on only 6 months data, and
are retrospective in nature e although the recruitment of patients
(and their experience of exacerbations) was relatively evenly
spread over a full calendar year. The decision to use 6-month data
was a practical one, and was intended to improve the accuracy of
data collected, given that (especially for moderate exacerbations)
these datawere largely based on patient recall. It will be interesting
to see the 1- and 2-year follow-up data on these patients, to see
whether a change in medication impacts this overall experience of
exacerbations.
Approximately one quarter of the patients recruited into DAC-
CORD had experienced an exacerbation in the 6 months prior to
entry. This could again be due to the inclusion criteria, in that pa-
tients who have experienced an exacerbation are more likely to
have their COPD maintenance treatment reviewed by their physi-
cian and thus be included in the study. Overall, and in the two
groups of patients according to ICS use, the most common treat-
ment for exacerbations was antibiotics, either alone or in combi-
nation with systemic steroids. An intriguing ﬁnding from the
INSPIRE (Investigating New Standards for Prophylaxis in Reducing
Exacerbations) study was that when patients were treated with
double-blind LAMA or LABA/ICS, physicians weremore likely to use
systemic steroids to manage exacerbations in patients receiving
LAMA, and were more likely to use antibiotics to manage exacer-
bations in patients receiving LABA/ICS [14]. This ﬁnding was not
replicated in the current study, with patients in the non-ICS group
being more likely to receive antibiotics than systemic steroids. The
reason for this difference is not clear, although this could reﬂect
local clinical practice or formulary guidance, or perhaps these pa-
tients preferred to avoid exposure to systemic steroids. It should be
noted, however, that patients in INSPIRE all had severe or very
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tions, and use of ICS was therefore ‘on label’.
GOLD 2010 classiﬁcation may again reveal a recruitment effect
into this study, in that approximately half of the patients were
classiﬁed as GOLD II. However, GOLD 2011 classiﬁcation was
consistent with a number of other such studies [15e17], with pa-
tients being much more likely to be classiﬁed as high risk due to
FEV1 than exacerbations. In particular, in the UK primary care
database review mentioned above, approximately 50% of the high-
risk C and D groups were classiﬁed as high risk according to FEV1
alone, approximately 30% due to exacerbations alone, and
approximately 20% according to both FEV1 and exacerbations e
exactly the same distribution as in DACCORD [7]. In DACCORD, CAT
and mMRC resulted in widely varying symptoms classiﬁcations e
again, consistent with other studies [18,19], including an analysis of
a subgroup of patients in the HEED (Health-Related Quality of Life
in COPD in Europe) study, in which, for example, 63.3% of the pa-
tients were classiﬁed as GOLD D according to CAT, but only 35.9% of
patients were GOLD D according to mMRC [19].
High levels of comorbidities were observed in this population,
with more than 50% of the patients reporting cardiovascular
comorbidities. This is again consistent with a number of other ‘real
world’ studies [7,20e24], and is a key difference between this type
of study and a randomised clinical trial. For example, in the UK
primary care database review 78.8% of the COPD population had at
least one comorbidity, most commonly cardiovascular (46.1%) [7].
Furthermore, in a Canadian claims database review of more than
900,000 patients with COPD, comorbidities with the highest claim
rates were psychiatric (for ambulatory care visits), diabetes (for
emergency department visits) and cardiovascular (for hospital-
isation), with each of these comorbidities responsible for higher
claim rates than COPD [24]. Some other studies have suggested a
correlation between CAT total score and comorbidities, such that
patients with higher CAT scores have higher levels of comorbidities
[25]; this was also observed in DACCORD, with a ﬁve-fold increase
in psychiatric disorders in patients in the CAT >30 group compared
with the CAT <10 group. Although CAT is a disease-speciﬁc health
status assessment, many of the items that it assesses could be
inﬂuenced by comorbid conditions.
In conclusion, DACCORD is a large, prospective, non-
interventional study. Although it cannot be truly described as an
epidemiology study (given the requirement for patients to be
initiating or changing bronchodilator treatment in order to be
eligible), the data reported here do provide an informative and
intriguing picture of COPD patients using primary and secondary
care in Germany, experiencing a high level of symptoms.
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